KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Other Non-Current Assets: 2009-2025

Historic Other Non-Current Assets for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Sep 2025 value amounting to $1.1 billion.

  • Vertex Pharmaceuticals' Other Non-Current Assets rose 10.89% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 10.89%. This contributed to the annual value of $999.3 million for FY2024, which is 11.62% up from last year.
  • Vertex Pharmaceuticals' Other Non-Current Assets amounted to $1.1 billion in Q3 2025, which was up 1.78% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Other Non-Current Assets registered a high of $1.1 billion during Q3 2025, and its lowest value of $49.3 million during Q1 2021.
  • Its 3-year average for Other Non-Current Assets is $836.9 million, with a median of $915.6 million in 2024.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Other Non-Current Assets plummeted by 79.72% in 2021 and then soared by 286.18% in 2023.
  • Quarterly analysis of 5 years shows Vertex Pharmaceuticals' Other Non-Current Assets stood at $110.8 million in 2021, then skyrocketed by 269.68% to $409.6 million in 2022, then spiked by 118.58% to $895.3 million in 2023, then rose by 11.62% to $999.3 million in 2024, then rose by 10.89% to $1.1 billion in 2025.
  • Its Other Non-Current Assets stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.0 billion for Q1 2025.